BAX vs SOLV: How Baxter International and Solventum Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and SOLV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and SOLV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across several healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, health information systems (clinical documentation, coding, and revenue-cycle software for hospitals), and purification and filtration (including water and biopharma filtration). The company makes money selling consumable medical products to hospitals and clinics, software and services to health systems, and filtration technology to industrial and life-science customers. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital, dental, and industrial end markets globally.

Full SOLV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• SOLV drivers: Recurring consumable and software revenue; Spin-off self-help and margin expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For SOLV, as a recent spin-off, Solventum carries meaningful debt taken on at separation and must prove it can grow organically after years inside 3M, where the business reportedly underinvested.

Pick BAX if you believe its drivers more; SOLV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and SOLV guides.

BAX. Baxter trades at a modest valuation (price-to-sales near 1x) that reflects both its low-growth profile and the balance-sheet overhang. Full-year 2026 guidance calls for roughly flat to 1% sales growth on a GAAP basis. Reported profitability has been distorted by special charges, so adjusted metrics tell a more stable story than headline GAAP figures.

SOLV. Solventum trades at a discount to faster-growing medtech peers, reflecting its slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The qualitative profile is a turnaround and self-help story: stabilize growth, reduce leverage, and expand margins. Successful deleveraging and portfolio reshaping are the key swing factors.

Headline figures (approximate, July 2026): BAX shows revenue (ttm, continuing ops) ~$10.7B, q1 2026 sales ~$2.7B, q1 2026 adjusted eps ~$0.36, market cap ~$11.5B; SOLV shows revenue (ttm) ~$8 billion, revenue growth low-single-digit, roughly flat to slightly up, operating margin ~20% on an adjusted basis, net debt elevated, inherited at the 3M separation.

BAX and SOLV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and SOLV exposure against your real portfolio. It is not an investment adviser.